Skip to main content
Full access
Case Report
Published Online: 7 December 2023

Let’s “Whippit” Away: Nitrous Oxide Misuse and Its Complications

Publication: American Journal of Psychiatry Residents' Journal
Nitrous oxide (N2O) was discovered by Joseph Priestley in 1772 and has been used in the medical and dental fields since 1844, when its anesthetic properties were realized. Alternative names include “laughing gas” and “nos.” Other benefits include analgesic and anxiolytic properties that are utilized in surgical procedures and childbirth. In health care settings today, N2O is mixed with at least 30% oxygen, and doses rarely surpass 40% N2O to prevent harmful adverse effects (1). Recreationally, N2O is unmixed. Upon entering alveoli, N2O dilutes gas (including oxygen), leading to hypoxia and, possibly, adverse effects, neurological and psychiatric sequelae, and death (2, 3).
Despite potential adverse effects, N2O is used recreationally for its euphoric, anxiolytic, and dissociative effects. It is most commonly misused in the form of whipped cream chargers, known as “whippits.” Alternative names include “whip-its,” “whippets,” and “hippie crack.” These chargers are legal, affordable, and easily obtained sources of N2O, leading to increased ease of access and, therefore, potential misuse. Whippits are discharged into a dispenser and inhaled orally via the dispenser directly or via a balloon or mask. Following inhalation, N2O dissolves rapidly in the bloodstream and reaches the brain within seconds, causing euphoria that lasts from seconds to minutes (2). N2O is hypothesized to activate mesolimbic dopaminergic neurons, which can lead to repetitive use and, ultimately, psychological dependence (4).
N2O misuse is the most prevalent of many types of inhalant misuse, commonly known as “huffing.” According to a 2019 national survey conducted by the U.S. Substance Abuse and Mental Health Services Administration, lifetime prevalence of N2O misuse by Americans ages 12 and older was 4.6%, or 12.64 million Americans. This same study identified the past-year prevalence of inhalant use to be 2.1 million Americans, including 730,000 first-time users (5, 6). Additionally, in 2019, the Global Drug Survey found N2O to be the 10th most popularly used drug worldwide (excluding tobacco, caffeine, and alcohol) (7). Despite its popularity, most people are unaware of any risks associated with N2O misuse. In a survey of 140 randomly selected participants in England, Ehirim et al. found that 91.6% of those familiar with N2O were unaware of any adverse effects (2). Here, we describe a case in which a patient was affected by adverse effects associated with N2O misuse, namely vitamin B12 deficiency.

Case Presentation

The patient was a 45-year-old man with a history of schizoaffective disorder, inhalant use disorder (in early remission), and alcohol use disorder (in sustained remission) who was referred to our neurology clinic for further evaluation of weakness, 10 months after cessation of severe N2O misuse. He had used 100 whippits daily for 12 months to cope with anxiety from a breakup and the COVID-19 pandemic. Throughout this period, he denied using other substances, including alcohol. He initially used fewer chargers but gradually increased the number as tolerance developed. His N2O misuse persisted until he awoke in bed barely able to move his legs. The acute-onset weakness was severe enough to prevent him from working and leaving home. He immediately discontinued using N2O and left his bed only to receive food deliveries and use the bathroom. Given the extent of his weakness, he ambulated by propping himself up on objects with his arms. Over 1 month, his weakness gradually improved such that he could walk, drive, and return to work. However, because his strength did not fully recover, despite 8 months of abstinence, he sought care from his primary care physician for further evaluation. Laboratory results revealed low vitamin B12 levels (156 pg/mL; normal range 180–914 pg/mL) but normal folate levels (16.0 ng/mL; normal values ≥5.9 ng/mL). He received vitamin B12 supplementation, but his strength only mildly improved over 2 months; therefore, he followed up with his primary care physician. A repeat vitamin B12 test revealed normal levels (289 pg/mL), leading to a neurology referral
Upon presentation to our clinic the following month, the patient’s weakness and altered gait were obvious. He reported tingling in his lower back and feet. He was alert and oriented x4, and his recent and distant memory were intact. His speech was fluent. A physical examination demonstrated lower-extremity weakness in dorsiflexion and eversion bilaterally and mild weakness in inversion on the right side. His reflexes were normal (grade 2+) in his upper extremities and knees but absent in both ankles. Bilateral foot drop, steppage gait, and a positive Romberg test were present. There was a decreased sensation to pinprick in the first interdigital space of each foot. Cranial nerves II to XII were intact, and his finger-to-nose and heel-to-shin testing were normal. The Babinski sign was negative. Given the neurological distribution, there was concern for bilateral peroneal neuropathy versus distal neurological injury in a stocking-glove distribution. The patient was scheduled for a lower-extremity electromyogram and referred to physical therapy. Repeat vitamin B12 testing was ordered. He rescheduled the electromyogram twice, did not present to his follow-up appointment, and was ultimately lost to follow-up. Months later, we learned that he died by suicide.

Discussion

N2O induces vitamin B12 deficiency by permanently oxidizing cobalt ions in vitamin B12. Vitamin B12 is a cofactor necessary for the conversion of homocysteine and methylmalonyl coenzyme A to methionine and succinyl coenzyme A, respectively, which are needed for methylation of myelin protein. Demyelination occurs in the central and peripheral nervous systems and can present as subacute combined degeneration (SCD). It should be noted that a normal vitamin B12 level does not necessarily reflect functional vitamin B12. Assessing homocysteine and methylmalonic acid levels, which will be elevated without functional vitamin B12, can more accurately reflect a true deficiency (3, 8). Other proposed etiologies of neurotoxicity include downstream effects of increased reactive oxygen species and prolonged N-methyl-d-aspartate receptor blockade (9).
As noted in other case reports, not all patients with neurological sequelae from N2O misuse have the typical presentation of SCD. Rather, they have varying distributions of weakness, paresthesia, and imbalance (10). Our patient did not have SCD; he had focal areas of residual weakness, paresthesia, and imbalance, which remained despite vitamin B12 returning to a normal level. Unfortunately, homocysteine or methylmalonic acid levels were not available. The findings from our patient are consistent with those of other patients, suggesting that despite abstinence and treatment of N2O-induced vitamin B12 deficiency, patients with significant N2O misuse can experience long-term neurological sequelae. This is especially concerning considering that younger people, who lack fully developed nervous systems, comprise the highest percentage of new misusers (5). Whether sequelae are permanent is yet to be confirmed. Unfortunately, with our patient lost to follow-up, it is unclear whether our recommended physical therapy and additional recovery time would have resulted in the full resolution of symptoms.
Other sequelae of N2O misuse are medical (dyspnea, wheezing, chest pain, and perioral erythema) and psychiatric (hallucinations, delusions, paranoia, and depression). A systematic review found 29 case reports discussing N2O as a cause of death, with multiple deaths resulting from asphyxiation due to hypoxia or from arrhythmias. There was one report of suicide after relapse (8). Regarding our patient, it is uncertain to what extent the sequelae contributed to his death by suicide. Both our patient and his family, who informed us of his death, consented to his case being shared so that his passion for science can live on through others learning from his story.
The significant morbidity from N2O misuse indicates a need for increased awareness. In the Ehirim et al. survey, 79.2% of 101 nonusers in the past 12 months indicated that they would likely try N2O in the next 3 months, with 93.9% of them reporting that they would be more comfortable experimenting in a social setting (2). Socially, misuse is seen at festivals and clubs (11). One contributing factor may be a lack of awareness of adverse effects. The majority of those surveyed indicated that it was “extremely important” to educate others about the adverse effects. If aware of the risks, some individuals indicated that they would use N2O in a safer environment (an unenclosed space), inform friends of risks, or not use N2O altogether (2). Screening for N2O misuse is especially important given that it is undetected by routine serum and urine tests. Although there is no widely recognized screener specifically for N2O, the National Institute on Drug Abuse’s tool, Screening to Brief Intervention, screens for N2O misuse and contains recommendations for clinicians (8, 12).
Providers should also be aware of treatment options. In addition to vitamin B12 repletion and physical therapy, authors of two case reports found reductions in use with oral or intramuscular naltrexone, with one group observing a daily charger consumption decrease of almost 98% after 1 month (13, 14). There is limited evidence for methionine supplementation (10, 1517).

Conclusions

Given the ease of access, relatively low cost, and short-lived euphoria of N2O, it is not surprising that it is used by so many to obtain a “legal high.” Furthermore, its popularity is especially alarming considering its prevalence among those without fully developed nervous systems. Given the prevalence of N2O misuse and its potential dangers, greater emphasis should be placed on screening for and improving psychoeducation about this potentially life-altering substance. With increased awareness, more patients can receive support, evaluation, and treatment to prevent developing the long-term and potentially life-long neurological sequelae experienced by our patient.

Key Points/Clinical Pearls

Nitrous oxide is more commonly misused than is recognized in health care settings and can cause significant morbidity and mortality.
The Screening to Brief Intervention is a tool that screens for nitrous oxide misuse and contains recommendations for clinicians.
If a patient has neurological symptoms in the context of substance use, consider vitamin B12 deficiency resulting from nitrous oxide misuse.
Low vitamin B12 levels or increased methylmalonic acid and homocysteine levels can indicate a need for vitamin B12 repletion.

Footnote

The author confirms that the details of this case have been disguised to protect patient privacy. Written consent for publication of this case was obtained from the patient’s family.

References

1.
Gillman MA: Mini-review: a brief history of nitrous oxide (N2O) use in neuropsychiatry. Curr Drug Res Rev 2019; 11:12–20
2.
Ehirim EM, Naughton DP, and Petróczi A: No laughing matter: presence, consumption trends, drug awareness, and perceptions of “hippy crack” (nitrous oxide) among young adults in England. Front Psychiatry 2018; 8:312
3.
Al-Sadawi M, Claris H, Archie C, et al: Inhaled nitrous oxide “whip-its!” causing subacute combined degeneration of spinal cord. Am J Med Case Rep 2018; 6:237–240
4.
Lew V, McKay E, and Maze M: Past, present, and future of nitrous oxide. Br Med Bull 2018; 125:103–119
5.
Key Substance Use and Mental Health Indicators in the United States: Results From the 2019 National Survey on Drug Use and Health. Health and Human Services pub no PEP20-07-01-001, NSDUH series H–55. Rockville, Md, Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, 2020. https://www.samhsa.gov/data/sites/default/files/reports/rpt29393/2019NSDUHFFRPDFWHTML/2019NSDUHFFR090120.htm
6.
Illicit drug use/misuse tables 1.97A, 1.97B: 2019 National Survey of Drug Use and Health (NSDUH) releases. Rockville, Md, Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, 2020. https://www.samhsa.gov/data/release/2019-national-survey-drug-use-and-health-nsduh-releases
7.
Winstock AR: GDS 2019 key findings report: executive summary. Global Drug Survey, 2019. https://www.globaldrugsurvey.com
8.
Garakani A, Jaffe RJ, Savla D, et al: Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: a systematic review of the case literature. Am J Addict 2016; 25:358–369
9.
Brunt TM, van den Brink W, and van Amsterdam J: Mechanisms involved in the neurotoxicity and abuse liability of nitrous oxide: a narrative review. Int J Mol Sci 2022; 23:14747
10.
Thompson AG, Leite MI, Lunn MP, et al: Whippits, nitrous oxide and the dangers of legal highs. Pract Neurol 2015; 15:207–209
11.
Kaar SJ, Ferris J, Waldron J, et al: Up: the rise of nitrous oxide abuse: an international survey of contemporary nitrous oxide use. J Psychopharmacol 2016; 30:395–401
12.
Adolescent substance use screening tools: Screening to Brief Intervention (S2BI). Bethesda, Md, National Institute on Drug Abuse, 2023. https://nida.nih.gov/nidamed-medical-health-professionals/screening-tools-prevention/screening-tools-adolescent-substance-use/adolescent-substance-use-screening-tools
13.
Ickowicz S, Brar R, and Nolan S: Case study: naltrexone for the treatment of nitrous oxide use. J Addict Med 2020; 14:e277–e279
14.
Staudenmaier PJ, Kane V, Iyer A, et al: A case report of a dual diagnosis patient: naltrexone for the treatment of severe nitrous oxide use disorder with associated neurological and psychiatric sequelae. J Scientific Innovat Med 2023; 6:2
15.
Stacy CB, Di Rocco A, and Gould RJ: Methionine in the treatment of nitrous-oxide-induced neuropathy and myeloneuropathy. J Neurol 1992; 239:401–403
16.
Swart G, Blair C, Lu Z, et al: Nitrous oxide-induced myeloneuropathy. Eur J Neurol 2021; 28:3938–3944
17.
Shulman RM, Geraghty TJ, and Tadros M: A case of unusual substance abuse causing myeloneuropathy. Spinal Cord 2007; 45:314–317

Information & Authors

Information

Published In

Go to American Journal of Psychiatry Residents' Journal
American Journal of Psychiatry Residents' Journal
Pages: 2 - 4

History

Published online: 7 December 2023
Published in print: December 7, 2023

Authors

Affiliations

Sean Sedore, D.O.
Dr. Sedore is a fourth-year resident in the Department of Psychiatry at Tripler Army Medical Center, Honolulu.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share